Injectable
Aurevia
Semaglutide
GLP-1 therapy delivered as clinical care.
- GLP-1 Receptor Therapy
- Appetite Control Support
- Titrated Weight Management
Starting at $190/month
Read More
Weight Management
Move the metabolism.
Keep the muscle.
Weight and metabolic care built for durable outcomes — GLP-1 and dual-incretin therapies delivered with the titration, labs and continuity a provider relationship provides. Every medication and peptide is sourced through licensed U.S. laboratories, prescribed only where clinically appropriate.
Protocols within this pillar
Provider-guided, personally titrated.
Who this is for
A pillar built for the long view.
Adults with a clinical indication for pharmacologic support
Whether the goal is meaningful weight reduction, glycemic control or reversing metabolic drift, candidacy is confirmed through clinical assessment and, where indicated, laboratory review.
Professionals who cannot afford a crash
Titration is planned, side effects are managed proactively and dose changes are matched to your tolerance — not to a marketing calendar.
Patients who have plateaued on GLP-1 monotherapy
Dual-incretin protocols and adjunctive care may be considered where clinically appropriate for those needing more depth of response.
Longevity-minded adults
Weight and metabolic health sit at the center of long-term risk. This pillar is treated as foundational — never cosmetic.
How provider-guided care works
One relationship, from intake onward.
01
Assessment
A confidential intake that maps symptoms, goals and history — the starting point for every plan.
02
Provider review
A US board-certified provider reviews your intake and, where indicated, orders baseline labs before prescribing.
03
Personalized protocol
Your GLP-1 or metabolic protocol is titrated to your tolerance and paired with nutrition and training scaffolding.
04
Ongoing oversight
Scheduled check-ins, dose refinement and de-escalation planning are built into the program — not sold as add-ons.
Science & evidence
Grounded in the literature.
We prescribe therapies with an established mechanism and a monitoring pathway our providers can execute reliably.
- —GLP-1 and dual GIP/GLP-1 agonists carry the strongest outpatient pharmacologic evidence base for weight and cardiometabolic outcomes.
- —Structured titration and lifestyle support materially improve tolerability and long-term adherence versus fixed-dose approaches.
- —Nutrition, protein targeting and resistance training are prescribed alongside medication to protect lean mass.
- —Monitoring cadence is chosen for clinical relevance — never to inflate touch-points.
Questions